These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 4953138)

  • 21. [Effect of Sadamin on lipid metabolism in patients with obliterative arteriosclerosis of lower limbs].
    Kiersnowska B; Bielawiec M; Lukjan H; Grabowski R; Korfel B
    Pol Tyg Lek; 1972 Jan; 27(4):133-5. PubMed ID: 5010169
    [No Abstract]   [Full Text] [Related]  

  • 22. The in-vivo-effect of E-aminocaproic acid (EACA) on human plasma fibrinolytic system.
    Niewiarowski S; Wolosowicz N
    Thromb Diath Haemorrh; 1966 May; 15(3):491-500. PubMed ID: 4865186
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of fibrinolysis activation on the peripheral blood circulation in occlusive vascular diseases].
    Bielawiec M; Lukjan H
    Med Monatsschr; 1971 Jul; 25(7):312-4. PubMed ID: 5563915
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
    Laursen B; Gormsen J
    Scand J Haematol; 1969; 6(6):402-8. PubMed ID: 5374117
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect of a single dose of heparin on the fibrinolytic activity of plasma euglobulins and studies on blood coagulation in patients with obliterative arteriosclerosis of the lower extremities].
    Cencora A
    Folia Med Cracov; 1973; 15(2):207-27. PubMed ID: 4758953
    [No Abstract]   [Full Text] [Related]  

  • 26. Blood zinc levels in patients with arteriosclerosis obliterans, thromboangiitis obliterans and Takayasu's disease.
    Atsumi T; Numano F
    Jpn Heart J; 1975 Nov; 16(6):664-9. PubMed ID: 241871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Activation of fibrinolysis after oral administration of D-glucitol-hexanicotinate. Preliminary data].
    Pinto A; Novo S; Avellone G; Vinci G
    Boll Soc Ital Cardiol; 1978; 23(4):641-5. PubMed ID: 757348
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical and experimental research on prolonged fibrinolytic treatment. 2. Activation of fibrinolysis by prolonged administration of nicotinic acid derivatives].
    De Nicola P; Gibelli A; Frandoli G; Turazza G
    Hemostase; 1965 Dec; 5(4):343-51. PubMed ID: 5880346
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical evaluation of Provasan].
    Wodniecki J; Wolański A
    Wiad Lek; 1970 Oct; 23(20):1791-3. PubMed ID: 5482235
    [No Abstract]   [Full Text] [Related]  

  • 30. Buerger's disease in Israel. Investigations on carboxyhemoglobin and serum cholesterol levels after smoking.
    Kjeldsen K; Mozes M
    Acta Chir Scand; 1969; 135(6):495-8. PubMed ID: 5368937
    [No Abstract]   [Full Text] [Related]  

  • 31. Platelet aggregability in chronic arterial occlusive diseases of the extremities.
    Kobayashi H; Mishima Y
    Thromb Res; 1980 Nov; 20(4):363-73. PubMed ID: 7209887
    [No Abstract]   [Full Text] [Related]  

  • 32. [Nicotinic acid and fibrinolysis in humans. I. Regional fibrinolysis (cerebral, of the upper extremity and of the lower extremity) caused by "arterial" administration of nicotinic acid].
    Tesi M
    Riv Crit Clin Med; 1967 Dec; 67(6):465-83. PubMed ID: 5603691
    [No Abstract]   [Full Text] [Related]  

  • 33. Carbon monoxide and peripheral arterial disease.
    Astrup P
    Scand J Clin Lab Invest Suppl; 1967; 99():193-7. PubMed ID: 6056923
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapeutic properties of xanthine nicotinate in the treatment of obliterating arteriopathies].
    Tardito E; Azzolini A; De Cristofaro A; Papacharalambus D
    Minerva Cardioangiol; 1972; 20(7):369-89. PubMed ID: 5050745
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical and coagulation physiological studies on a protease from Aspergillus ochraceus (preliminary report)].
    Vogel G; Grossmann K; Huyke R; Zuber W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(1):125-31. PubMed ID: 4134261
    [No Abstract]   [Full Text] [Related]  

  • 36. [Thrombolytic action of the tissue activator profibrinolysin and nicotinic acid].
    Andreenko GV; Migalina LA
    Vopr Med Khim; 1973; 19(4):371-4. PubMed ID: 4788286
    [No Abstract]   [Full Text] [Related]  

  • 37. [Fibrinolysis activation and the kininogen system and prostaglandin activity in the blood of patients with arteriosclerosis].
    Lukjan H; Bielawiec M; Bodzenta A
    Acta Haematol Pol; 1980; 11(3):121-7. PubMed ID: 6905632
    [No Abstract]   [Full Text] [Related]  

  • 38. [Relationship between beta lipoprotein concentration and the activity of the fibrinolytic system in arteriosclerosis and in postpartum].
    Musiatowicz J; Skrzydlewski Z; Obrzut A
    Pol Tyg Lek; 1967 Nov; 22(46):1760-2. PubMed ID: 5584347
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical considerations and functional data on the use of the association of kallikrein and meso-inositol hexanicotinate in the therapy of obliterating arteriopathy].
    Blasi A; Licciardello M
    Clin Ter; 1966 Jul; 38(2):121-58. PubMed ID: 5990194
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostaglandins in therapy of cardiovascular disease.
    Szczeklik A; Gryglewski RJ
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():345-54. PubMed ID: 3159222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.